Email this article Octreotide and direct/indirect lung injury
, Zahra Pezeshki, Samira Choopani, Mehdi Nematbakhsh Abstract
Background and purpose: Lung injury is one of the most important diseases, which is accompanied by hypoxemia, organ failure, and a high mortality rate. There are several symptoms and causes of lung injuries. In the past years, special attention has been given to investigating the pathophysiology and the treatment of this disease. Octreotide, as an anti-inflammatory, anti-secretory, tissue-repairing, and anti-fibrotic drug, has been considered and administered for the treatment of lung injury. This review article considered the pharmacological effects of octreotide on physiopathological conditions in patients or animal models that have direct or indirect lung injury.
Search strategy and findings: Keywords including “octreotide” OR “sandostatin” AND “lung injury” OR “ARDS” OR “respiratory distress” OR “lung fibrosis” were searched in the database of PubMed, and 44 articles were found. According to the direct or indirect lung injury, the articles were classified.
Conclusion: It appears that octreotide is a protective drug for the treatment of direct and indirect lung injuries, exhibiting anti-inflammatory, anti-hypersecretory, anti-fibrotic, and anti-neutrophil permeability effects, while also increasing endogenous antioxidants. However, there is still room for extensive research to fully clarify the effectiveness of octreotide for direct or indirect lung injury.
Keywords
Full Text:
PDFReferences
Thi Hong Nguyen N, Ou TY, Huy LD, Shih CL, Chang YM, Phan TP, et. al. A global analysis of COVID-19 infection fatality rate and its associated factors during the Delta and Omicron variant periods: an ecological study. Front Public Health. 2023;11:1145138,1-15.DOI: 10.3389/fpubh.2023.1145138.
2. Mehri A, Sotoodeh Ghorbani S, Farhadi-Babadi K, Rahimi E, Barati Z, Taherpour N, et al. Risk factors associated with severity and death from COVID-19 in Iran: a systematic review and meta-analysis study. J Intensive Care Med. 2023;38(9):825-837.DOI: 10.1177/08850666231166344.
3. Shahbazi F, Khazaei S. Socio-economic inequality in global incidence and mortality rates from coronavirus disease 2019: an ecological study. New Microbes New Infect. 2020;38:100762,1-4.DOI: 10.1016/j.nmni.2020.100762.
4. Fatemi B, Rezaei S, Peikanpour M, Dastan F, Saffaei A. Efficacy of intravenous immunoglobulins (IVIG) in COVID-19 patients: a systematic review and meta-analysis. Res Pharm Sci. 2023;18(4):346-357.DOI: 10.4103/1735-5362.378082.
5. Kanokkangsadal P, Mingmalairak C, Mukkasombat N, Kuropakornpong P, Worawattananutai P, Khawcharoenporn T, et al. Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial. Res Pharm Sci. 2023;18(6):592-603.DOI: 10.4103/1735-5362.389947.
6. Yazdani M, Khezri J, Hadizadeh N, Amir Zakaria JZ, Naderi M, Mahmoodian S, et al. Depinar, a drug that potentially inhibits the binding and entry of COVID-19 into host cells based on computer-aided studies. Res Pharm Sci. 2021;16(3):315-325. DOI: 10.4103/1735-5362.314830.
7. Zhang L, Mei S, Zhu B, Zhao Z. Trends in research on acute lung injury/acute respiratory distress syndrome associated with viral pneumonia from 1992 to 2022: a 31-year bibliometric analysis. Front Med (Lausanne). 2023;10:1158519,1-11.DOI: 10.3389/fmed.2023.1158519.
8. Ferguson ND, Frutos-Vivar F, Esteban A. Mortality rates in patients with ARDS: what should be the reference standard? In: Vincent JL, editors. Intensive care medicine. New York: Springer; 2003. pp. 231-242.DOI: 10.1007/978-1-4757-5548-0_22.
9. Stapleton RD, Wang BM, Hudson LD, Rubenfeld GD, Caldwell ES, Steinberg KP. Causes and timing of death in patients with ARDS. Chest. 2005;128(2):525-532.DOI: 10.1378/chest.128.2.525.
10. Matuschak GM, Lechner AJ. Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. Mo Med. 2010;107(4):252-258. PMID: 20806836.
11. Cao K, Grunstein RR, Ho KY, Sullivan CE. The effect of octreotide on breathing and the ventilatory response to CO2 in conscious dogs. Eur Respir J. 1998;11(6):1376-1381.DOI: 10.1183/09031936.98.11061376.
12. Xing XZ, Wang HJ, Qu SN, Huang CL. Combining therapy of octreotide and glucocorticoid in the treatment of a lung adenocarcinoma patient with acute respiratory distress syndrome. J Transl Crit Care Med. 2019;1(1):4-6.DOI: 10.4103/jtccm.jtccm_8_18.
13. Brown SR, Fernandez C, Bertellotti R, Asensio JA. Blunt rupture of the thoracic duct after severe thoracic trauma. Trauma Surg Acute Care Open. 2018;3(1):e000183,1-2.DOI: 10.1136/tsaco-2018-000183.
14. Paran H, Neufeld D, Mayo A, Shwartz I, Singer P, Kaplan O, et al. Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg. 1995;181(2):121-124. PMID: 7627383.
15. Paran H, Mayo A, Paran D, Neufeld D, Shwartz I, Zissin R, et al. Octreotide treatment in patients with severe acute pancreatitis. Dig Dis Sci. 2000;45(11):2247-2251.DOI: 10.1023/a:1026679106463.
16. Tug T, Kara H, Karaoglu A, Karatas F, Turgut NH, Ayan E, et al. The effect of octreotide, an analog of somatostatin, on bleomycin-induced interstitial pulmonary fibrosis in rats. Drug Chem Toxicol. 2013;36(2):181-186.DOI: 10.3109/01480545.2012.710618.
17. Kara H, Karatas F, Tug T, Canatan H, Karaoglu A. Protective effect of octreotide on intra-tracheal bleomycin-induced oxidative damage in rats. Exp Toxicol Pathol. 2010;62(3):235-241.DOI: 10.1016/j.etp.2009.03.012.
18. Ge R, Wang F, Peng Z. Advances in biomarkers for diagnosis and treatment of ARDS. Diagnostics (Basel). 2023;13(21):3296,1-16.DOI: 10.3390/diagnostics13213296.
19. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.DOI: 10.1001/jama.2012.5669.
20. Morisawa K, Fujitani S, Taira Y, Kushimoto S, Kitazawa Y, Okuchi K, et al. Difference in pulmonary permeability between indirect and direct acute respiratory distress syndrome assessed by the transpulmonary thermodilution technique: a prospective, observational, multi-institutional study. J Intensive Care. 2014;2(1):24,1-8. DOI: 10.1186/2052-0492-2-24.
21. Gonzales JN, Lucas R, Verin AD. The acute respiratory distress syndrome: mechanisms and perspective therapeutic approaches. Austin J Vasc Med. 2015;2(1):1009,1-13.PMID: 26973981.
22. Sargen K, Kingsnorth AN. Acute pancreatitis: an overview of emerging pharmacotherapy. BioDrugs. 1998;10(5):359-371.DOI: 10.2165/00063030-199810050-00003.
23. Zayed Y, Askari R. Respiratory distress syndrome (archived). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.PMID: 30855895.
24. Araz O. Current pharmacological approach to ARDS: the place of bosentan. Eurasian J Med. 2020;52(1):81-85.DOI: 10.5152/eurasianjmed.2020.19218.
25. Acute Respiratory Distress Syndrome Network; Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308.DOI: 10.1056/nejm200005043421801.
26. Spadaro S, Park M, Turrini C, Tunstall T, Thwaites R, Mauri T, et al. Biomarkers for acute respiratory distress syndrome and prospects for personalised medicine. J Inflamm (Lond). 2019;16:1,1-11.DOI: 10.1186/s12950-018-0202-y.
27. Zhang J, Ge P, Liu J, Luo Y, Guo H, Zhang G, et al. Glucocorticoid Treatment in Acute Respiratory Distress Syndrome: An Overview on Mechanistic Insights and Clinical Benefit. Int J Mol Sci. 2023;24(15):12138.DOI: 10.3390/ijms241512138.
28. Qadir N, Chang SY. Pharmacologic treatments for acute respiratory distress syndrome. Crit Care Clin. 2021;37(4):877-893.DOI: 10.1016/j.ccc.2021.05.009.
29. Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci. 2020;21(5):1682,1-27.DOI: 10.3390/ijms21051682.
30. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet. 1993;25(5):375-391.DOI: 10.2165/00003088-199325050-00004.
31. Zigam QA, Al-Zubaidy AA, Abbas WJ, Al-Mudhafar RH. Cardioprotective effects of octreotide against sepsis-induced cardiotoxicity in mice. Arch Razi Inst. 2023;78(1):53-61.DOI: 10.22092/ARI.2022.358339.2201.
32. Sun H, Zou S, Candiotti KA, Peng Y, Zhang Q, Xiao W, et al. Octreotide attenuates acute kidney injury after hepatic ischemia and reperfusion by enhancing autophagy. Sci Rep. 2017;7:42701,1-9.DOI: 10.1038/srep42701.
33. Yang J, Sun H, Takacs P, Zhang Y, Liu J, Chang Y, et al. The effect of octreotide on hepatic ischemia-reperfusion injury in a rabbit model. Transplant Proc. 2013;45(6):2433-2438.DOI: 10.1016/j.transproceed.2013.02.112.
34. Casnici C, Lattuada D, Crotta K, Truzzi MC, Corradini C, Ingegnoli F, et al. Anti-inflammatory effect of somatostatin analogue octreotide on rheumatoid arthritis synoviocytes. Inflammation. 2018;41(5):1648-1660.DOI: 10.1007/s10753-018-0808-5.
35. Chen Z, Fu H, Fang J, Yang J, Zhu X, Cheng B, et al. Preventive and therapeutic significance of octreotide combined with lansoprazole on post-ERCP pancreatitis and its effect on serum amylase, inflammatory factors and immune function. Exp Ther Med. 2021;21(3):251,1-8.DOI: 10.3892/etm.2021.9682.
36. Dai GF, Wang Z, Zhang JY. Octreotide protects doxorubicin-induced cardiac toxicity via regulating oxidative stress. Eur Rev Med Pharmacol Sci. 2018;22(18):6139-6148.DOI: 10.26355/eurrev_201809_15954.
37. Kalyoncu S, Yilmaz B, Demir M, Tuncer M, Bozdag Z, Ince O, et al. Octreotide and lanreotide decrease ovarian ischemia-reperfusion injury in rats by improving oxidative and nitrosative stress. J Obstet Gynaecol Res. 2020;46(10):2050-2058.DOI: 10.1111/jog.14379.
38. Cavdar S, Acar AG, Camyar A, Hür E, Sozmen EY, Sen S, et al. Effect of octreotide on oxidative stress in the erythrocyte and kidney tissue in adriamycin-induced experimental nephrotic syndrome model. J Bras Nefrol. 2024; 46(1):18-28.DOI: 10.1590/2175-8239-JBN-2022-0180en.
39. Buscail L, Delesque N, Estève JP, Saint-Laurent N, Prats H, Clerc P, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. 1994;91(6):2315-2319.DOI: 10.1073/pnas.91.6.2315.
40. Chaudhary NI, Roth GJ, Hilberg F, Müller-Quernheim J, Prasse A, Zissel G, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976-985. DOI: 10.1183/09031936.00152106.
41. Günal AI, Duman S, Sen S, Unsal A, Terzioğlu E, Akçiçek F, et al. By reducing TGF beta 1, octreotide lessens the peritoneal derangements induced by a high glucose solution. J Nephrol. 2001;14(3):184-189. PMID: 11439742.
42. Lebtahi R, Moreau S, Marchand-Adam S, Debray MP, Brauner M, Soler P, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med. 2006;47(8):1281-1287.PMID: 16883006.
43. Bang UC, Semb S, Nojgaard C, Bendtsen F. Pharmacological approach to acute pancreatitis. World J Gastroenterol. 2008;14(19):2968-2976. DOI: 10.3748/wjg.14.2968.
44. Baldysiak-Figiel A, Jong-Hesse YD, Lang GK, Lang GE. Octreotide inhibits growth factor-induced and basal proliferation of lens epithelial cells in vitro. J Cataract Refract Surg. 2005;31(5):1059-1064.DOI: 10.1016/j.jcrs.2004.08.056.
45. Sener G, Cetinel S, Erkanli G, Gedik N, Yeğen BC. Octreotide ameliorates sepsis-induced pelvic inflammation in female rats by a neutrophil-dependent mechanism. Peptides. 2005;26(3):493-499. DOI: 10.1016/j.peptides.2004.10.013.
46. Lebtahi R, Moreau S, Marchand-Adam S, Debray MP, Brauner M, Soler P, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med. 2006;47(8), 1281-1287.PMID: 16883006.
47. van den Blink B, Wijsenbeek MS, Hoogsteden HC. Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2010;23(6):515-520.DOI: 10.1016/j.pupt.2010.08.001.
48. Ozer Cakir O, Findik S. Diclofenac sodium treatment ameliorates extrapancreatic organ injuries in a murine model of acute pancreatitis induced by caerulein. Gastroenterol Res Pract. 2018;2018:9829208,1-6.DOI: 10.1155/2018/9829208.
49. Palmon P, Glazer JM, Long MT. Postprandial hypotension in the intensive care unit due to portal hypertension and Coronavirus disease 2019: A case report. A A Pract. 2021;15(6):e01485.DOI: 10.1213/xaa.0000000000001485.
50. Kaçmaz A, Polat A, User Y, Tilki M, Ozkan S, Sener G. Octreotide improves reperfusion-induced oxidative injury in acute abdominal hypertension in rats. J Gastrointest Surg. 2004;8(1):113-119.DOI: 10.1016/j.gassur.2003.09.026.
51. Vlastos D, Zeinah M, Ninkovic-Hall G, Vlachos S, Salem A, Asonitis A, et al. The effects of ischaemic conditioning on lung ischaemia-reperfusion injury. Respir Res. 2022;23(1):351,1-13.DOI: 10.1186/s12931-022-02288-z.
52. Zhao Z, Duan L, Gao D, Yao Y, Deng K, Xing B, et al. Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study. Ann Transl Med. 2022;10(13):734,1-13. DOI: 10.21037/atm-22-414.
53. Anger M, Hofmann J, Ruf B, Steinborn M, Reber D, Warncke K, et al. Cough-induced chylothorax in a two-year-old boy-case report and review of the literature. BMC Pediatr. 2023;23(1):416,1-6. DOI: 10.1186/s12887-023-04221-9.
54. Sooklin L, Anand AJ, Rajadurai VS, Chandran S. Management of large congenital chylous ascites in a preterm infant: fetal and neonatal interventions. BMJ Case Rep. 2020;13(9):e235849.DOI: 10.1136/bcr-2020-235849.
55. Dori L, Smaropoulos E, Tagarakis G, Foroulis CN, Zarogoulidis P, Huang H, et al. Successful treatment of familial congenital chylothorax by ligation of the thoracic duct: a case report. Respir Med Case Rep. 2017;21:66-68.DOI: 10.1016/j.rmcr.2017.03.017.
56. Afsharpaiman S, Rezaee Zavareh MS, Torkaman M. Low dose of octreotide can be helpful in the management of congenital chylothorax. Iran Red Crescent Med J. 2015;17(10):e18915,1-3.DOI: 10.5812/ircmj.18915.
57. Szabados E, Toth K, Mezosi E. Use of octreotide in the treatment of chylopericardium. Heart Lung. 2011;40(6):574-575.DOI: 10.1016/j.hrtlng.2010.01.004.
58. Sousa PR, Leitão H, Camacho MC, Nunes JL. Idiopathic congenital chylothorax treated with octreotide. BMJ Case Rep. 2010;2010: bcr06.2009.1950.
DOI: 10.1136/bcr.06.2009.1950.
59. Siu SLY, Lam DSY. Spontaneous neonatal chylothorax treated with octreotide. J Paediatr Child Health. 2006;42(1-2):65-67.DOI: 10.1111/j.1440-1754.2006.00788.x.
60. Gul M, Seydanoglu A, Ayan M, Cander B, Erayman I, Girisgin S. Dose-dependent effects of octreotide on plasma activities of IL-6 and lung tissue levels of malondialdehyde in sepsis. Crit Care. 2007;11(Suppl 2):P12. DOI: 10.1186/cc5172.
61. Guo H, Chen J, Suo D. Clinical efficacy and safety of ulinastatin plus octreotide for patients with severe acute pancreatitis. Zhonghua Yi Xue Za Zhi. 2015;95(19):1471-1474.PMID: 26178495.
62. Crestani B, Chapron J, Wallaert B, Bergot E, Delaval P, Israel-Biet D, et al. Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study. Eur Respir J. 2011;39(3):772-775. DOI: 10.1183/09031936.00113011.
63. Kagawa H, Stringham J, Selzman C, Goodwin M, Frye L, Raman S, et al. Case report of needle disruption of the retroperitoneal lymph nodes for refractory chylothorax after double lung transplantation. Transplant Proc. 2023;55(8):1981-1983.DOI: 10.1016/j.transproceed.2023.08.003.
64. Oza CM, Khadilkar V, Kadam S, Khadilkar A. Response to sirolimus in a case of diffuse congenital hyperinsulinaemic hypoglycaemia due to homozygous KCNJ11 mutation. BMJ Case Rep. 2022;15(11): e252708,1-4.DOI: 10.1136/bcr-2022-252708.
65. Chalasti M, Iordanou C, Kratiras Z, Stylianaki A, Trigka EA, Lakiotaki E, et al. Experimental isolation and preservation of solid organs before transplantation: effects of pretreatment using four different molecules. J Int Med Res. 2020;48(6):300060520933452,1-19.DOI: 10.1177/0300060520933452.
66. Wang R, Yang F, Wu H, Wang Y, Huang Z, Hu B, et al. High-dose versus low-dose octreotide in the treatment of acute pancreatitis: a randomized controlled trial. Peptides. 2013;40:57-64.DOI: 10.1016/j.peptides.2012.12.018.
67. Al-Sahaf M. Postoperative chylothorax. Shanghai Chest. 2021;5:28,1-8. DOI: 10.21037/shc-2019-amp-07.
68. Rudrappa M, Paul M. Chylothorax. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.PMID: 29083798.
69. Barnidge M, Vea R, Rau B, Chu Q, Behm W, D'Agostino H. Management of postoperative chylothorax utilizing percutaneous CT-guided drainage. J La State Med Soc. 2008;160(4):221-224; quiz 224, 233. PMID: 18828464.
70. Fiedler F, Jauernig G, Keim V, Richter A, Bender HJ. Octreotide treatment in patients with necrotizing pancreatitis and pulmonary failure. Intensive Care Med. 1996;22(9):909-915.DOI: 10.1007/BF02044115.
71. Jackson S, Jnah AJ. Chylothorax: A stepwise approach to diagnosis and treatment. Neonatal Netw. 2021;40(6):386-392.DOI: 10.1891/11-t-705.
72. Wehbe K, Duminil L, Bertrand A, Kianmanesh R, Graesslin O, Raimond E. Complete remission of medically treated luteinized thecomas with sclerosing peritonitis. J Gynecol Obstet Hum Reprod. 2021;50(6):101734.DOI: 10.1016/j.jogoh.2020.101734.
73. Foo NH, Hwang YS, Lin CC, Tsai WH. Congenital chylothorax in a late preterm infant and successful treatment with octreotide. Pediatr Neonatol. 2011;52(5):297-301.DOI: 10.1016/j.pedneo.2011.06.011.
74. Smets K. X-linked myotubular myopathy and chylothorax. Neuromuscul Disord. 2008;18(2):183-184.DOI: 10.1016/j.nmd.2007.10.004.
75. Caty MG, Hilfiker ML, Azizkhan RG, Glick PL. Successful treatment of congenital chylous ascites with a somatostatin analogue. Pediatr Surg Int. 1996;11(5-6):396-397.DOI: 10.1007/bf00497824.
76. Kühn MWM, Blagieva R, Beha D, Hänle M, Reister F, Henne-Bruns D, et al. A 31-year-old pregnant woman with refractory hypercalcemia. Internist (Berl). 2012;53(12):1490-1495.DOI: 10.1007/s00108-012-3149-8.
77. Mondello S, Fodale V, Cannavò S, Aloisi C, Almoto B, Buemi M, et al. Hypophosphatemia as unusual cause of ARDS in Cushing's syndrome secondary to ectopic CRH production. A case report. ScientificWorldJournal. 2008;8:138-144.DOI: 10.1100/tsw.2008.20.
78. Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology. 2001;60(2):141-145. DOI: 10.1159/000055311.
79. van Diepen S, Sobey A, Lewanczuk R, Singh G, Sidhu S, Zibdawi M, et al. A case of acute respiratory distress syndrome responsive to methylene blue during a carcinoid crisis. Can J Anaesth. 2013;60(11):1085-1088.DOI: 10.1007/s12630-013-0026-4.
80. Elshafie O, Nair J, Busaidi M, Riyami B, Hussein S, Woodhouse N. Chromogranin-A levels and refractory bronchospasm in interstitial lung disease: a preliminary report on the favourable response to octreotide. Br J Med Med Res. 2015;7(8):705-710. DOI: 10.9734/BJMMR/2015/15655.
81. Kim DS, Park SK, Choi WH, Kim TW, Choi YY, Jeon SC, et al. Pneumocystis carinii pneumonia associated with a rapid reduction of cortisol level in a patient with ectopic ACTH syndrome treated by octreotide and ketoconazole. Exp Clin Endocrinol Diabetes. 2000;108(2):146-150. DOI: 10.1055/s-2000-5810.
82. Abuhamda AF, Elsous A, Al-Saadi N, Al-Dadah M. A rare case of congenital chylothorax in a Palestinian neonate. Respir Med Case Rep. 2019;28:100937,1-3.
DOI: 10.1016/j.rmcr.2019.100937.
83. Huda T, Mohan A, Parwez MM, Pandya B. An unusual combination of three rare complications: pleuro-pancreatic fistula, chylous ascites, and renal vein thrombosis, in a case of acute severe pancreatitis. Surg J (N Y). 2019;5(4):e188-e191. DOI: 10.1055/s-0039-1700807.
84. Reiterer F, Grossauer K, Morris N, Uhrig S, Resch B. Congenital pulmonary lymphangiectasis. Paediatr Respir Rev. 2014;15(3):275-280.DOI: 10.1016/j.prrv.2014.05.002.
85. Talluri SK, Nuthakki H, Tadakamalla A, Talluri J, Besur S. Chylous ascites. N Am J Med Sci. 2011;3(9):438-440.
DOI: 10.4297/najms.2011.3438.
86. Kalas MA, Leon M, Chavez LO, Canalizo E, Surani S. Vascular complications of pancreatitis. World J Clin Cases. 2022;10(22):7665-7673. DOI: 10.12998/wjcc.v10.i22.7665.
87. Kaman L, Behera A, Singh R, Katariya RN. Internal pancreatic fistulas with pancreatic ascites and pancreatic pleural effusions: recognition and management. ANZ J Surg. 2001;71(4):221-225. DOI: 10.1046/j.1440-1622.2001.02077.x.
88. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med. 1994;330(17):1198-1210.DOI: 10.1056/nejm199404283301706.
89. Talvik R, Liigant A, Sissak HM, O'Konnel-Bronina N. Respiratory failure in acute pancreatitis. Intensive Care Med. 1977;3(2):97-98. DOI: 10.1007/bf01683069.
90. Popa CC, Badiu DC, Rusu OC, Grigorean VT, Neagu SI, Strugaru CR. Mortality prognostic factors in acute pancreatitis. J Med Life. 2016;9(4):413-418. PMID: 27928447.
91. Ibadov RA, Arifjanov AS, Ibragimov SK, Abdullajanov BR. Acute respiratory distress-syndrome in the general complications of severe acute pancreatitis. Ann Hepatobiliary Pancreat Surg. 2019;23(4):359-364. DOI: 10.14701/ahbps.2019.23.4.359.
92. Tian H, Zhang X, Wu C, Chen L, Ying R, Ye J, et al. Effects of baicalin and octreotide on the serum TNF-alpha level and apoptosis in multiple organs of rats with severe acute pancreatitis. Inflammation. 2009;32(3):191-201. DOI: 10.1007/s10753-009-9120-8.
93. Zhang XP, Zhang L, Yang P, Zhang RP, Cheng QH. Protective effects of baicalin and octreotide on multiple organ injury in severe acute pancreatitis. Dig Dis Sci. 2008;53(2):581-591.DOI: 10.1007/s10620-007-9868-3.
94. Huang L, Zhu H, Gu J. Octreotide and continuous hemofiltration versus continuous hemofiltration alone in severe acute pancreatitis complicated with acute respiratory distress syndrome. J Coll Physicians Surg Pak. 2019;29(8):785-787. DOI: 10.29271/jcpsp.2019.08.785.
95. Browne GW, Pitchumoni CS. Pathophysiology of pulmonary complications of acute pancreatitis. World J Gastroenterol. 2006;12(44):7087-7096.DOI: 10.3748/wjg.v12.i44.7087.
96. Yehya N, Xin Y, Oquendo Y, Cereda M, Rizi RR, Margulies SS. Cecal ligation and puncture accelerates development of ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2015;308(5):L443-L451. DOI: 10.1152/ajplung.00312.2014.
97. Bastarache JA, Matthay MA. Cecal ligation model of sepsis in mice: new insights. Crit Care Med. 2013;41(1):356-357. DOI: 10.1097/CCM.0b013e318270e3ee.
98. Chimenti L, Morales-Quinteros L, Puig F, Camprubi-Rimblas M, Guillamat-Prats R, Gómez MN, et al. Comparison of direct and indirect models of early induced acute lung injury. Intensive Care Med Exp. 2020;8(Supll 1):62,1-13. DOI: 10.1186/s40635-020-00350-y.
99. Bora SE, Erdoğan A, Erdoğan MA, Yiğitturk G, Çakır A, Erbaş O. Short-term protective effect of octreotide on the lungs of rats with experimentally induced sepsis. Ulus Travma Acil Cerrahi Derg. 2022;28(1):8-14. DOI: 10.14744/tjtes.2020.02589.
100. Kaçmaz A, Polat A, User Y, Tilki M, Ozkan S, Sener G. Octreotide: a new approach to the management of acute abdominal hypertension. Peptides. 2003;24(9):1381-1386.DOI: 10.1016/j.peptides.2003.09.004.
101. Zhang S, Tang C, Wang X. Octreotide activates autophagy to alleviate lipopolysaccharide-induced human pulmonary epithelial cell injury by inhibiting the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway. Bioengineered. 2022;13(1):217-226.DOI: 10.1080/21655979.2021.2012908.
102. Liu R, Wang CH, Huang MH, Li X, Qiang O, Tang CW. Therapeutic effect of somatostatin on acute respiratory distress syndrome in experimental rats. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006;37(3):412-415.PMID: 16761421.
103. Limón-Pacheco J, Gonsebatt ME. The role of antioxidants and antioxidant-related enzymes in protective responses to environmentally induced oxidative stress. Mutat Res. 2009;674(1-2):137-147.DOI: 10.1016/j.mrgentox.2008.09.015.
104. Karatas F, Kara H, Servi S, Tug T, Erulas FA, Koca M. Investigation of antioxidant vitamins (A, E, C) and lipid peroxidation levels in rats injected N-(1,3-benzothiazol-2-yl)-N-(4,5-dihydro-1H-imidazol-2-yl) amine. Molecules. 2005;10(8):922-928.DOI: 10.3390/10080922.
105. Karatas F, Koca M, Kara H, Servi S. Synthesis and oxidant properties of novel (5-bromobenzofuran-2-yl)(3-methyl-3-mesitylcyclobutyl)ketonethiosemicarbazone. Eur J Med Chem. 2006;41(5):664-669.
DOI: 10.1016/j.ejmech.2006.01.003.
106. Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. 2010;23(4):243-252.DOI: 10.1089/jamp.2009.0775.
107. Nosaka N, Martinon D, Moreira D, Crother TR, Arditi M, Shimada K. Autophagy protects against developing increased lung permeability and hypoxemia by down regulating inflammasome activity and IL-1β in LPS plus mechanical ventilation-induced acute lung injury. Front Immunol. 2020;11:207,1-12.DOI: 10.3389/fimmu.2020.00207.
108. Zhao H, Chen H, Xiaoyin M, Yang G, Hu Y, Xie K, et al. Autophagy activation improves lung injury and inflammation in sepsis. Inflammation. 2019;42(2):426-439.DOI: 10.1007/s10753-018-00952-5.
109. Mohamed DZ, El-Sisi AEE, Sokar SS, Shebl AM, Abu-Risha SE. Targeting autophagy to modulate hepatic ischemia/reperfusion injury: a comparative study between octreotide and melatonin as autophagy modulators through AMPK/PI3K/AKT/mTOR/ULK1 and Keap1/Nrf2 signaling pathways in rats. Eur J Pharmacol. 2021;897:173920,1-16.DOI: 10.1016/j.ejphar.2021.173920.
110. Shibutani ST, Saitoh T, Nowag H, Münz C, Yoshimori T. Autophagy and autophagy-related proteins in the immune system. Nat Immunol. 2015;16(10):1014-1024. DOI: 10.1038/ni.3273.
111. Fukui K, Amari S, Yotani N, Kosaki R, Hata K, Kosuga M, et al. A Neonate with mucopolysaccharidosis type VII with intractable ascites. AJP Rep. 2023;13(1):e25-e28.DOI: 10.1055/a-2028-7784.
112. Pfammatter R, Quattropani C, Reichen J, Göke B, Wagner AC. Treatment of hepatic hydrothorax and reduction of chest tube output with octreotide. Eur J Gastroenterol Hepatol. 2001;13(8):977-980.
DOI: 10.1097/00042737-200108000-00019.
113. Lu M, Cavazzoni E, Selvadurai H, Burren JM. Paediatric acute respiratory distress syndrome: consider the role of lymphatics. BMJ Case Rep. 2022;15(7):e245543,1-7.DOI: 10.1136/bcr-2021-245543.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.